SCHEMBL16845095

SCHEMBL16845095

CC1CCCN(C2CCN(C(=O)c3ccc(C(=O)NCc4ccccc4C(F)(F)F)cc3)CC2)C1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 8/20 0.49
▸ ADRA1A P35348 8/20 0.49
▸ EPHX1 P07099 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ PPARG P37231 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ L3MBTL3 Q96JM7 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ SLC6A4 P31645 1/20 0.46
▸ HRH3 Q9Y5N1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL18185594 0.97 EPHX2 (0.49) EPHX2ADRA1AEPHX1CYP3A4CYP2D6
SCHEMBL16845169 0.82 ADRA1A (0.53) ADRA1AL3MBTL3L3MBTL1
Trifluoroacetic Acid SCHEMBL18185650 0.82 ADRA1A (0.47) ADRA1AKDM4EALDH1A1L3MBTL3L3MBTL1
SCHEMBL16845091 0.81 ADRA1A (0.62) ADRA1AKDM4EMEN1ALDH1A1KMT2A
SCHEMBL16823982 0.81 ADRA1A (0.52) ADRA1AL3MBTL3L3MBTL1
SCHEMBL16823988 0.81 ADRA1A (0.50) ADRA1AL3MBTL3L3MBTL1
SCHEMBL16845211 0.81 ADRA1A (0.50) ADRA1AL3MBTL3L3MBTL1
Trifluoroacetic Acid SCHEMBL18185575 0.81 ADRA1A (0.57) ADRA1AKDM4EMEN1ALDH1A1KMT2A
SCHEMBL16845162 0.79 MAPK14 (0.52) ADRA1ASLC6A4HRH3
SCHEMBL16845151 0.79 ADRA1A (0.54) ADRA1AKDM4EALDH1A1L3MBTL3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160318866-A1 SUBSTITUTED BIPIPERIDINYL DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-11-03 — — US disclosed
US-20160318866-A1 SUBSTITUTED BIPIPERIDINYL DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-11-03 — — US disclosed
WO-2015091415-A1 SUBSTITUTED BIPIPERIDINYL DERIVATIVES AS ADRENORECEPTOR ALPHA 2C ANTAGONISTS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318866-A1 SUBSTITUTED BIPIPERIDINYL DERIVATIVES TNNI3, TNNC1, FABP3 EPHX2 2809/4885ADRA1A 1241/4885EPHX1 2310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback